Recently, this view was challenged by a study demonstrating that CSF p‐tau231 is the first emerging p‐tau species in preclinical AD, reaching abnormal levels even before p‐tau217 and p‐tau181 (Suarez‐Calvet et al, 2020). This evidence concerns the gene MAPT and Alzheimer disease.